Press Releases

VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update

February, 01 2021

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and Drug Administration (“FDA”) to include new information in the product label for AMZEEQ® (minocycline) topical foam, 4% referencing the low propensity of P. acnes strains to develop resistance to minocycline, the active ingredient in AMZEEQ. AMZEEQ is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years…

Read More

VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update

January, 29 2021

BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares of common stock at a purchase price of $2.37 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. After deducting placement agent’s fees, advisory fees and other offering expenses payable by VYNE, VYNE received net proceeds of approximately $46.7 million. VYNE intends to use the net proceeds from the offering for working capital and general corporate purposes. In addition to…

Read More

VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

January, 26 2021

BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”),  today announced that it has entered into definitive agreements with institutional and accredited investors for the sale of an aggregate of 21,097,046 shares of its common stock at a purchase price of $2.37 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offering is expected to close on or about January 28, 2021, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds of the…

Read More

VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company

January, 21 2021

BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ® (minocycline) topical foam, 4% and ZILXI® (minocycline) topical foam, 1.5%. AMZEEQ, the first topical minocycline to be approved by the U.S. Food and Drug Administration (“FDA”) for any condition, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults and…

Read More

VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week

January, 05 2021

BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in two panel presentations at the LifeSci Partners 10th Annual Healthcare Corporate Access Event. Panel Presentation Details Title: Dermatology Innovation: Addressing Physician and Patient Underserved Needs Day: Thursday, January 7 Time: 2:00pm Eastern Time Registration Link: https://wsw.com/webcast/lifesci/panel9/2316951     Title: Executing a Successful Product Launch During a Pandemic Day: Friday, January 8 Time: 2:00pm Eastern Time Registration Link: https://wsw.com/webcast/lifesci/panel14/2387307 The format will be a virtual presentation with the opportunity for Q&A at the…

Read More

VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne

December, 17 2020

BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). The Company, in consultation with the FDA, has established the key elements of the Phase 3 program to support a New Drug Application (NDA) for FCD105 (3% minocycline / 0.3% adapalene foam), the first ever minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. The End-of-Phase…

Read More